A SURVEY OF RHEUMATOLOGY PATIENTS' SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS

被引：0
|
作者：
Ng, C. R. [1 ]
Samec, S. [1 ]
Kavanagh, P. [1 ]
Mccarthy, G. [1 ]
Donnelly, S. [1 ]
Wilson, A. G. [1 ]
机构：
[1] Mater Misericordiae Univ Hosp, Dept Rheumatol, Dublin, Ireland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2981
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0805
引用
收藏
页码：1427 / 1427
页数：1
相关论文
共 50 条
  • [21] OUTCOMES FOLLOWING SWITCHING FROM ORIGINATOR TO BIOSIMILAR IN CHILDREN AND YOUNG PEOPLE WITH JIA
    Kearsley-Fleet, L.
    Baildam, E.
    Beresford, M.
    Douglas, S.
    Foster, H.
    Southwood, T.
    Hyrich, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 285 - 285
  • [22] Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
    Fitzgerald, Timothy
    Melsheimer, Richard
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Morrison, Laura
    Woodruff, Kimberly
    Lin, Iris
    Emond, Bruno
    BIOLOGICS-TARGETS & THERAPY, 2021, 15 : 1 - 15
  • [23] Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough?
    Lie, G.
    Sciascia, S.
    Cuadrado, M. J.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 27 (02) : 220 - 223
  • [24] Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
    Kristensen, Lars Erik
    Alten, Rieke
    Puig, Luis
    Philipp, Sandra
    Kvien, Tore K.
    Mangues, Maria Antonia
    van den Hoogen, Frank
    Pavelka, Karel
    Vulto, Arnold G.
    BIODRUGS, 2018, 32 (05) : 397 - 404
  • [25] Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
    Lars Erik Kristensen
    Rieke Alten
    Luis Puig
    Sandra Philipp
    Tore K. Kvien
    Maria Antonia Mangues
    Frank van den Hoogen
    Karel Pavelka
    Arnold G. Vulto
    BioDrugs, 2018, 32 : 397 - 404
  • [26] SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB: EFFICACY AND SAFETY IN A COHORT OF PATIENTS WITH ESTABLISHED BEHCET'S DISEASE
    Venerito, V.
    Lopalco, G.
    Cantarini, L.
    Fabiani, C.
    Nivuori, M.
    Cacciapaglia, F.
    Galeazzi, M.
    Lapadula, G.
    Iannone, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1494 - 1495
  • [27] Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
    Onishchenko, Kateryna
    Alexopoulos, Stamatia Theodora
    Curiale, Cinzia
    Tarallo, Miriam
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [28] Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behcet's disease
    Lopalco, Giuseppe
    Venerito, Vincenzo
    Cantarini, Luca
    Emmi, Giacomo
    Prisco, Domenico
    Iannone, Florenzo
    INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (05) : 719 - 722
  • [29] Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Kadivar, Mohammad
    Molin, Daniel
    Angelison, Leif
    Hammarlund, Per
    Olin, Marie
    Torp, Jorgen
    Grip, Olof
    Nilson, Stefan
    Hertervig, Erik
    Lillienau, Jan
    Marsal, Jan
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
  • [30] Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK
    Tarallo, Miriam
    Onishchenko, Kateryna
    Alexopoulos, Stamatia T.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1162 - 1170
12345